BNR (BNR) Stock Price & Analysis
BNR (BNR) rose 0.00% to USD 9.05 as of July 25, 2026 at 04:24 UTC, according to Nexqual real-time market data.
BNR last closed at USD 9.05; the session ranged USD 9.05–9.05 on volume of 153 shares. Market capitalization is $95.39M, with a 52-week range of USD 5.31–41.72 (NGM). Source: Nexqual, July 25, 2026 at 04:24 UTC.
Key Statistics (as of July 25, 2026 at 04:24 UTC)
| Price | USD 9.05 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 9.05 |
| Open | USD 9.05 |
| Day Range | USD 9.05 – 9.05 |
| 52-Week Range | USD 5.31 – 41.72 |
| Volume | 153 shares |
| Market Cap | $95.39M |
| Exchange | NGM |
Technical Analysis (BNR)
Nexqual's technical model rates BNR "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.7 (neutral) |
| vs SMA50 | Below (USD 10.52) |
| MACD | -0.27 (negative) |
Analyst Ratings (BNR)
Wall Street analysts rate BNR "None", per Nexqual as of July 25, 2026 at 04:24 UTC.
| Consensus Rating | None |
|---|
Earnings (BNR)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-03-31 | USD -18.1 vs est -13.9 ▼ miss |
| 2022-12-31 | USD -21.1 vs est -19 ▼ miss |
| 2022-09-30 | USD -23.3 vs est -18.8 ▼ miss |
| 2022-06-30 | USD -25 vs est -18.5 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Financials & Fundamentals (BNR)
| Total Revenue | $514.43M |
|---|---|
| Revenue Growth (YoY) | -18.90% |
| Gross Margin | +74.55% |
| Operating Margin | -17.46% |
| Profit Margin | -11.53% |
| ROE | -10.90% |
| Debt / Equity | 9.85 |
| Current Ratio | 3.05 |
| Total Cash | $446.00M |
| Total Debt | $50.86M |
| Free Cash Flow | $-18.97M |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Financial Health Score (BNR)
Nexqual rates BNR's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:24 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -17% |
| Balance Sheet | Strong — $446M cash vs $51M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$19M, burning cash |
| Efficiency | Critical — ROE -11%, ROA -4.5% |
Ownership (BNR)
| Insider Ownership | +4.01% |
|---|---|
| Institutional Ownership | +46.67% |
| Shares Outstanding | 8.81M |
| Float | 3.32M |
| Short % of Float | +0.49% |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Leadership (BNR)
BNR is led by Yusheng Han (age 46), Founder, Chairman & CEO, per Nexqual as of July 25, 2026 at 04:24 UTC.
| Founder, Chairman & CEO | Yusheng Han (age 46) |
|---|---|
| Vice President of Finance | Xiaozhi Hu (age 41) |
| CTO & Director | Zhihong Zhang (age 49) |
Major Backers & Investors (BNR)
Notable institutional backers of BNR include Kynam Capital Management, LP, CRCM LP, Renaissance Technologies, according to Nexqual as of July 25, 2026 at 04:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kynam Capital Management, LP | 13.93% |
| CRCM LP | 3.2% |
| Renaissance Technologies | 0.4% |
| Sumitomo Mitsui Trust Group, Inc. | 0.34% |
| Amova Asset Management Americas Inc | 0.34% |
| Bank of America Corporation | 0.33% |
| HSG Holding Ltd | 0.24% |
| Redwood Wealth Management Group, LLC | 0.21% |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LEGN | Legend Biotech Corporation | USD 22.22 | ▼ 5.57% |
| NBP | NovaBridge Biosciences | USD 1.77 | ▲ 1.72% |
| NRIX | Nurix Therapeutics, Inc. | USD 23.38 | ▼ 0.93% |
| PRLD | Prelude Therapeutics Incorporat | USD 3.83 | ▼ 2.42% |
| PCVX | Vaxcyte, Inc. | USD 54.66 | ▼ 2.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:24 UTC. This page is informational and not investment advice.